Challenges: Cell transplantation and gene therapy in muscular dystrophy
Citations Over TimeTop 15% of 1992 papers
Abstract
Duchenne's muscular dystrophy (DMD), which affects 1/3500 live male births, involves a progressive degeneration of skeletal and cardiac muscle, leading to early death. The protein dystrophin is lacking in DMD and present, but defective, in the allelic, less severe, Becker muscular dystrophy and is also missing in the mdx mouse. Experiments on the mdx mouse have suggested two possible therapies for these myopathies. Implantation of normal muscle precursor cells (mpc) into mdx skeletal muscle leads to the conversion of dystrophin-negative fibres to -positive, with consequent improvement in muscle histology. Direct injection of dystrophin cDNA into skeletal or cardiac muscle also gives rise to dystrophin-positive fibres. Although both appear promising, there are a number of questions to be answered and refinements to be made before either technique could be considered possible as treatments for myopathies in man.
Related Papers
- → Synergistic effect of combined intramyocardial CD34+ cells and VEGF2 gene therapy after MI(2006)65 cited
- → Cardiomyopathy in Muscular Dystrophy Workshop 28–30 September 2003, Tucson, Arizona(2004)5 cited
- Studies on progressive muscular dystrophy. I. Effects of adenosinetriphosphate and its related compounds on progressive muscular dystrophy.(1965)
- Studies on progressive muscular dystrophy. IV. Effects of original amino acids mixture on progressive muscular dystrophy.(1967)
- → Hereditary muscular dystrophy in MDX mice as a homologous model for introduction of cell technologies in the treatment of progressive muscular dystrophies in humans(2004)1 cited